Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis (NTLC75-ITA)

15. september 2026 oppdatert av: Ognjen Barčot, MD, PhD, University Hospital of Split

Relative Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis After Right Colectomy: A Prospective Observational Pilot Study

This prospective single-center pilot cohort will include 40 consecutive adults undergoing elective right colectomy with a Barcelona ileotransverse anastomosis using an NTLC75/SR75 linear stapler. A sensor mounted externally on the stapler handle will record relative mechanical signals during two calibration closures without firing and two standard stapler activations. The main objectives are to obtain at least 35 technically valid final cross-stapling recordings and to estimate the association between the normalized final maximum signal and C-reactive protein on postoperative day 3. Clinical treatment is unchanged and follow-up continues through postoperative day 90.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Two close-only calibration measurements will be recorded once on double-walled small bowel and colon located on the resection-specimen side, outside the tumor and resection margins, with the anvil toward the mesentery, without firing or consuming additional reloads. The first standard activation forms the ileotransverse anastomotic channel without cross-stapling, with the anvil in the colon and reload jaw in the small bowel. The final closure is oriented with the device tip toward the small bowel so that knife travel proceeds from colon to small bowel and crosses two existing staple lines. The surgeon measures flattened tissue lengths and both cross-stapling distances with a sterile ruler to the nearest whole millimeter. Raw signals are preserved; forward and return branches are resampled to 200 normalized-time points. The signal is not calibrated as absolute force, is not shown to the surgeon and does not influence care. Other curve features and clinical outcomes are exploratory.

Studietype

Observasjonsmessig

Registrering (Antatt)

40

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Split, Kroatia, 21000
        • University Hospital of Split, Department of Surgery
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adults scheduled for elective right colectomy for operable right-sided colon cancer with planned primary Barcelona ileotransverse anastomosis using NTLC75/SR75.

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Elective right colectomy for histologically confirmed or clinically or radiologically suspected operable right-sided colon cancer
  • Planned primary Barcelona ileotransverse anastomosis using NTLC75/SR75
  • Capacity to understand the study and provide written informed consent

Exclusion Criteria:

  • Emergency surgery
  • No planned or performed primary anastomosis
  • Another anastomotic technique or stapler model
  • Withdrawal or inability to consent
  • Intraoperative change of plan preventing the planned measurement procedure

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Elective Right Colectomy Cohort

Adults undergoing elective right colectomy with a Barcelona ileotransverse anastomosis using NTLC75/SR75 as standard clinical care. Relative mechanical signals are recorded passively during two close-only calibration closures without firing and two standard stapler activations.

An external DF9-40 sensor mounted on the NTLC75 handle passively records relative mechanical signals. One close-only calibration recording is obtained on double-walled small bowel and one on double-walled colon on the resection-specimen side, outside the tumor and resection margins, with the anvil toward the mesentery, without firing. Signals are also recorded during standard ITA channel formation (anvil in colon; reload jaw in small bowel; no cross-stapling) and final closure (tip toward small bowel; knife travel from colon to small bowel across two existing staple lines). The signal is not shown to the surgeon and does not affect clinical care.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participants With a Technically Valid Final Cross-Stapling Signal Record
Tidsramme: Intraoperative, during the final cross-stapling activation

Number and percentage of all 40 enrolled participants with a complete and technically valid final cross-stapling signal record. A valid record includes a complete forward branch, an identifiable reference return branch, no peak-obscuring saturation, no loss of sensor contact, and successful application of the locked signal-processing algorithm. Missing or invalid records remain in the denominator. Prespecified feasibility target: at least 35 of 40 participants.

Intraoperative, during the final cross-stapling activation
C-Reactive Protein Concentration on Postoperative Day 3 in Relation to the Normalized Final Maximum Signal
Tidsramme: Postoperative day 3

Routine-care serum C-reactive protein in mg/L, analyzed continuously in association with the normalized maximum amplitude of the final cross-stapling forward branch using a scatterplot, Pearson or Spearman correlation, and simple linear regression.

Postoperative day 3

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
CloseMax During Small-Bowel Close-Only Calibration
Tidsramme: Intraoperative, during the small-bowel close-only calibration

Maximum baseline-corrected relative signal amplitude during complete stapler closure on the double-walled small bowel located on the resection-specimen side, without firing. Reported in relative signal units.

Intraoperative, during the small-bowel close-only calibration
Maximum Signal Amplitude During ITA and Final Cross-Stapling Activations
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Maximum baseline-corrected amplitude of each forward and return signal branch, calculated separately for the ileotransverse anastomotic-channel and final cross-stapling activations. Reported in relative signal units.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Inter-Rater Agreement for Manual Curve Classification
Tidsramme: Through study completion and before database lock, an anticipated 16 months

Two independent raters blinded to C-reactive protein values and clinical outcomes classify technical validity, curve morphology, sticking, and irregularity for the ileotransverse anastomotic-channel and final cross-stapling recordings. Agreement between the two initial categorical ratings is quantified using Cohen's kappa before consensus resolution.

Through study completion and before database lock, an anticipated 16 months
C-Reactive Protein Concentration
Tidsramme: Postoperative days 1 and 3

Routine-care serum C-reactive protein concentration recorded separately on postoperative days 1 and 3 and reported in mg/L. The prespecified association between postoperative-day-3 CRP and the normalized final cross-stapling maximum remains the second primary outcome.

Postoperative days 1 and 3
Highest Clavien-Dindo Complication Grade
Tidsramme: From the index operation through postoperative day 90

Highest Clavien-Dindo grade assigned to any postoperative complication experienced by each participant through postoperative day 90. Participants without a complication are recorded as having no Clavien-Dindo complication.

From the index operation through postoperative day 90
Participants With Anastomosis-Related Events
Tidsramme: From the index operation through postoperative day 90

Number and percentage of participants with anastomotic leak, anastomotic bleeding, perianastomotic collection or abscess, anastomosis-related radiologic or endoscopic intervention, reoperation, or surgical revision. Each event type is reported separately.

From the index operation through postoperative day 90
Length of Postoperative Hospital Stay
Tidsramme: From the index operation to discharge from the index hospitalization, assessed through postoperative day 90

Number of calendar days from the index operation to discharge from the index hospitalization.

From the index operation to discharge from the index hospitalization, assessed through postoperative day 90
CloseMax During Colon Close-Only Calibration
Tidsramme: Intraoperative, during the colon close-only calibration

Maximum baseline-corrected relative signal amplitude during complete stapler closure on the double-walled colon located on the resection-specimen side, without firing. Reported in relative signal units.

Intraoperative, during the colon close-only calibration
CloseMax During Ileotransverse Anastomotic Channel Formation
Tidsramme: Intraoperative, during the stapler activation forming the ileotransverse anastomotic channel

Maximum baseline-corrected relative signal amplitude during the closing phase preceding the standard stapler activation used to form the ileotransverse anastomotic channel without cross-stapling. Reported in relative signal units.

Intraoperative, during the stapler activation forming the ileotransverse anastomotic channel
CloseMax During Final Cross-Stapling
Tidsramme: Intraoperative, during the final cross-stapling activation

Maximum baseline-corrected relative signal amplitude during the closing phase preceding the final cross-stapling activation. Reported in relative signal units.

Intraoperative, during the final cross-stapling activation
Normalized Time to Maximum Signal Amplitude
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Position of the maximum baseline-corrected amplitude within each signal branch, expressed as a percentage of that branch's total duration from 0% to 100%. Calculated separately for the forward and return branches of both activations.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Signal-Branch Duration During ITA and Final Cross-Stapling Activations
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Actual elapsed duration of each forward and return signal branch, calculated separately for the ileotransverse anastomotic-channel and final cross-stapling activations. Reported in seconds from the preserved raw timestamps.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Signal Peak Count During ITA and Final Cross-Stapling Activations
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Number of signal peaks identified by the locked signal-processing algorithm in each 200-point normalized-time branch. Calculated separately for the forward and return branches of both activations.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Maximum Signal Slope During ITA and Final Cross-Stapling Activations
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Maximum positive slope of each 200-point normalized-time signal branch, calculated using the locked signal-processing algorithm. Reported in relative signal units per normalized-time point and calculated separately for both activations.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Area Under the Signal Curve During ITA and Final Cross-Stapling Activations
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Area under each baseline-corrected 200-point normalized-time signal branch, calculated separately for the forward and return branches of both activations. Reported in relative signal units multiplied by normalized time.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Signal Amplitude Variability During ITA and Final Cross-Stapling Activations
Tidsramme: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Standard deviation of the baseline-corrected amplitudes across each 200-point normalized-time signal branch. Calculated separately for the forward and return branches of both activations and reported in relative signal units.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Leukocyte Count
Tidsramme: Postoperative days 1 and 3

Routine-care peripheral blood leukocyte count recorded separately on postoperative days 1 and 3 and reported as ×10^9/L.

Postoperative days 1 and 3
Neutrophil Count
Tidsramme: Postoperative days 1 and 3

Routine-care peripheral blood absolute neutrophil count recorded separately on postoperative days 1 and 3 and reported as ×10^9/L.

Postoperative days 1 and 3
Lymphocyte Count
Tidsramme: Postoperative days 1 and 3

Routine-care peripheral blood absolute lymphocyte count recorded separately on postoperative days 1 and 3 and reported as ×10^9/L.

Postoperative days 1 and 3
Neutrophil-to-Lymphocyte Ratio
Tidsramme: Postoperative days 1 and 3

Neutrophil-to-lymphocyte ratio calculated from the absolute neutrophil and lymphocyte counts obtained on the same postoperative day. Recorded separately on postoperative days 1 and 3 and reported as a unitless ratio.

Postoperative days 1 and 3
Serum Albumin Concentration
Tidsramme: Postoperative days 1 and 3

Routine-care serum albumin concentration recorded separately on postoperative days 1 and 3 and reported in g/L.

Postoperative days 1 and 3
Serum Creatinine Concentration
Tidsramme: Postoperative days 1 and 3

Routine-care serum creatinine concentration recorded separately on postoperative days 1 and 3 and reported in µmol/L.

Postoperative days 1 and 3
Estimated Glomerular Filtration Rate
Tidsramme: Postoperative days 1 and 3

Laboratory-reported estimated glomerular filtration rate recorded separately on postoperative days 1 and 3 and reported in mL/min/1.73 m².

Postoperative days 1 and 3
Participants With a Major Postoperative Complication
Tidsramme: From the index operation through postoperative day 90

Number and percentage of participants experiencing at least one major postoperative complication, defined as Clavien-Dindo grade III, IV, or V.

From the index operation through postoperative day 90
Comprehensive Complication Index Score
Tidsramme: From the index operation through postoperative day 90

Comprehensive Complication Index score calculated from all postoperative complications experienced by each participant through postoperative day 90. Reported on the standard continuous scale from 0, indicating no complication, to 100, indicating death.

From the index operation through postoperative day 90
Participants With All-Cause Readmission Within 30 Days
Tidsramme: From discharge after the index hospitalization through postoperative day 30

Number and percentage of participants with at least one unplanned all-cause hospital readmission by postoperative day 30.

From discharge after the index hospitalization through postoperative day 30
Participants Undergoing Reoperation Within 30 Days
Tidsramme: From the index operation through postoperative day 30

Number and percentage of participants undergoing at least one unplanned surgical reoperation for any cause by postoperative day 30.

From the index operation through postoperative day 30
All-Cause Mortality Within 30 Days
Tidsramme: From the index operation through postoperative day 30

Number and percentage of participants who die from any cause by postoperative day 30.

From the index operation through postoperative day 30
All-Cause Mortality Within 90 Days
Tidsramme: From the index operation through postoperative day 90

Number and percentage of participants who die from any cause by postoperative day 90.

From the index operation through postoperative day 90

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. oktober 2026

Primær fullføring (Antatt)

3. november 2027

Studiet fullført (Antatt)

29. januar 2028

Datoer for studieregistrering

Først innsendt

8. september 2026

Først innsendt som oppfylte QC-kriteriene

15. september 2026

Først lagt ut (Faktiske)

22. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Patient-level data will not be made public because the small single-center surgical cohort carries a material re-identification risk.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere